The use of β-blockers appears to be safe and significantly improves survival at mid-term follow-up among patients with COPD who are undergoing CABG. A comparison study showed that patients receiving β-blockers had a mortality rate of 7.7%, compared with an 18.3% rate for those who did not. Rates of COPD exacerbation were similar for both groups.

Abstract: Annals of Thoracic Surgery, February 2013.